Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Purchased by Algert Global LLC

Algert Global LLC boosted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS) by 26.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,697 shares of the company’s stock after buying an additional 2,617 shares during the quarter. Algert Global LLC’s holdings in Keros Therapeutics were worth $201,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of KROS. Vanguard Group Inc. increased its position in shares of Keros Therapeutics by 5.4% during the fourth quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company’s stock worth $30,981,000 after purchasing an additional 100,691 shares in the last quarter. Darwin Global Management Ltd. grew its stake in Keros Therapeutics by 10.7% during the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company’s stock worth $26,707,000 after buying an additional 163,403 shares during the last quarter. Geode Capital Management LLC increased its position in Keros Therapeutics by 5.5% during the fourth quarter. Geode Capital Management LLC now owns 765,436 shares of the company’s stock worth $12,120,000 after buying an additional 39,815 shares during the period. Lynx1 Capital Management LP acquired a new position in Keros Therapeutics during the fourth quarter worth approximately $8,612,000. Finally, American Century Companies Inc. lifted its stake in Keros Therapeutics by 10.5% in the fourth quarter. American Century Companies Inc. now owns 328,920 shares of the company’s stock valued at $5,207,000 after buying an additional 31,251 shares during the last quarter. Institutional investors and hedge funds own 71.56% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of Keros Therapeutics stock in a transaction that occurred on Wednesday, April 9th. The stock was purchased at an average price of $10.13 per share, for a total transaction of $9,464,033.54. Following the completion of the purchase, the insider now directly owns 4,392,737 shares of the company’s stock, valued at approximately $44,498,425.81. This trade represents a 27.01% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.60% of the stock is currently owned by corporate insiders.

Keros Therapeutics Stock Down 2.0%

Shares of Keros Therapeutics stock opened at $13.47 on Wednesday. The firm has a market cap of $547.08 million, a price-to-earnings ratio of -2.59 and a beta of 1.32. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37. The company’s 50-day simple moving average is $12.27 and its 200-day simple moving average is $23.83.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Tuesday, May 6th. The company reported $3.62 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million for the quarter, compared to analysts’ expectations of $84.62 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. During the same quarter in the previous year, the firm posted ($1.21) EPS. Equities research analysts anticipate that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Analysts Set New Price Targets

KROS has been the topic of a number of research reports. Wedbush restated a “neutral” rating and set a $15.00 target price on shares of Keros Therapeutics in a research report on Tuesday, April 1st. Truist Financial dropped their price objective on shares of Keros Therapeutics from $43.00 to $25.00 and set a “buy” rating on the stock in a research note on Wednesday, April 9th. Cantor Fitzgerald cut shares of Keros Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday, January 21st. Guggenheim reissued a “neutral” rating on shares of Keros Therapeutics in a report on Friday, January 17th. Finally, Oppenheimer dropped their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating on the stock in a research report on Thursday, January 16th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $37.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.